Citadel Advisors
OREX

Citadel Advisors’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Citadel Advisors’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-30,000
Closed -$87K – 8582
2017
Q2 		$87K Buy
30,000
+12,000
+67% +$36K ﹤0.01% 6954
2017
Q1 		$62K Buy
+18,000
New +$71K ﹤0.01% 6999
2016
Q3 		– Sell
-3,100
Closed -$13K – 8356
2016
Q2 		$13K Buy
3,100
+860
+38% +$3.89K ﹤0.01% 6712
2016
Q1 		$13K Sell
2,240
-490
-18% -$6.36K ﹤0.01% 6576
2015
Q4 		$47K Sell
2,730
-3,750
-58% -$89.4K ﹤0.01% 7377
2015
Q3 		$137K Buy
6,480
+2,590
+67% +$88.8K ﹤0.01% 6622
2015
Q2 		$193K Sell
3,890
-5,350
-58% -$320K ﹤0.01% 6376
2015
Q1 		$723K Buy
9,240
+6,550
+243% +$406K ﹤0.01% 4384
2014
Q4 		$163K Sell
2,690
-9,230
-77% -$464K ﹤0.01% 6212
2014
Q3 		$508K Buy
11,920
+4,790
+67% +$257K ﹤0.01% 4599
2014
Q2 		$441K Buy
7,130
+1,570
+28% +$91.3K ﹤0.01% 4562
2014
Q1 		$361K Sell
5,560
-3,760
-40% -$254K ﹤0.01% 4800
2013
Q4 		$525K Buy
9,320
+660
+8% +$37.1K ﹤0.01% 3972
2013
Q3 		$532K Buy
8,660
+3,820
+79% +$259K ﹤0.01% 3749
2013
Q2 		$283K Buy
+4,840
New +$298K ﹤0.01% 4359

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors's OREX Position: Q3 2017 in Review

Citadel Advisors sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2017, closing a stake of 20,920 shares — an estimated $51.1K sold.

Citadel Advisors first reported a position in OREX in Q2 2013 and held it in 14 quarters. The position peaked at $8.26M in Q3 2013. 42 funds tracked by Wall St. Rank hold OREX as of Q3 2017.

  • Citadel Advisors reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Citadel Advisors sold 20,920 Orexigen Therapeutics, Inc. shares in Q3 2017, an estimated $51.1K.
  • Citadel Advisors first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 14 quarters.
  • Citadel Advisors's Orexigen Therapeutics, Inc. position peaked at $8.26M in Q3 2013.
  • 42 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2017.

Based on Citadel Advisors's 13F filing for Q3 2017, filed 9 Nov 2017.